Compare · ARGX vs EIKN
ARGX vs EIKN
Side-by-side comparison of argenx SE (ARGX) and Eikon Therapeutics Inc. (EIKN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and EIKN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $48.42B, about 92.6x EIKN ($522.7M).
- Over the past year, ARGX is up 25.7% and EIKN is down 34.7% - ARGX leads by 60.4 points.
- ARGX has hit the wire 2 times in the past 4 weeks while EIKN has been quiet.
- ARGX has more recent analyst coverage (25 ratings vs 6 for EIKN).
- Company
- argenx SE
- Eikon Therapeutics Inc.
- Price
- $780.08-1.00%
- $9.67-9.54%
- Market cap
- $48.42B
- $522.7M
- 1M return
- +11.90%
- -12.41%
- 1Y return
- +25.72%
- -34.71%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2026
- News (4w)
- 2
- 0
- Recent ratings
- 25
- 6
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
- SEC Form 6-K filed by argenx SE
- argenx announces Annual General Meeting of Shareholders on May 6, 2026
- SEC Form 20-F filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx upgraded by Deutsche Bank
- SEC Form 6-K filed by argenx SE
- argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
- SEC Form 6-K filed by argenx SE
Latest EIKN
- Eikon Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates
- SEC Form 10-K filed by Eikon Therapeutics Inc.
- SEC Form 4 filed by Chief Operating Officer Klobuchar Michael A
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Frazier Kenneth C
- SEC Form 4 filed by Officer Perlmutter Roger M
- SEC Form 4 filed by Officer Thorner Benjamin Bruno
- SEC Form 4 filed by Chief Medical Officer Baynes Roy D.
- SEC Form 4 filed by Chief Financial Officer Bowie Alfred Lloyd Jr.